Balancing disease eradication with the emergence of multidrug-Resistant HIV in test-and-treat policies

Clinical Infectious Diseases

Volumn 56, Issue 12, 2013, Pages 1797-1799

  Jena, Anupam B ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

drug resistance; human immunodeficiency virus; test and treat

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE ERADICATION; HEALTH BEHAVIOR; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOPROPHYLAXIS; INTENTION TO TREAT ANALYSIS; LARGE SCALE PRODUCTION; LUNG INFECTION; MATHEMATICAL MODEL; MEN WHO HAVE SEX WITH MEN; MULTIDRUG RESISTANCE; NOTE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH; SEXUALLY TRANSMITTED DISEASE; SURVIVAL RATE; TEST AND TREAT POLICY; UNITED STATES; VIRUS STRAIN; VIRUS TRANSMISSION;

DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; TEST AND TREAT;

HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MODELS, STATISTICAL;

EID: 84878311568     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit159     Document Type: Note

References (19)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early an-tiretroviral therapy. N Engl J Med 2011; 365:493-505.
2. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.
3. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.
4. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 an-tiretroviral therapy. N Engl J Med 2013; 368:218-30.
5. Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368:207-17.
6. Thompson MA, Aberg JA, Hoy JF, et al. An-tiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
7. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-8.
8. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-404.
9. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
10. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active an-tiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-6.
11. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis 2011; 52: 1046-9.
12. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretrovi-ral treatment in the United States. Ann Intern Med 2010; 153:778-89.
13. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
14. Sorensen SW, Sansom SL, Brooks JT, et al. A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States. PLoS One 2012; 7:e29098.
15. Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
16. Van Damme L, Corneli A, Ahmed K, et al. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22.
17. Baeten JM, Celum C. Antiretroviral preexpo-sure prophylaxis for HIV prevention. N Engl J Med 2013; 368:83-4.
18. Thigpen MC, Rose CE, Paxton LA. Antire-troviral preexposure prophylaxis for HIV prevention. N Engl J Med 2013; 368:82-3.
19. Lakdawalla D, Sood N, Goldman D. HIV breakthroughs and risky sexual behavior. Quart J Econ 2006; 121:1063-102.